What is HC Wainwright’s Estimate for PVLA FY2030 Earnings?

Palvella Therapeutics, Inc. (NASDAQ:PVLA) – Analysts at HC Wainwright issued their FY2030 earnings per share estimates for shares of Palvella Therapeutics in a research note issued to investors on Monday, February 9th. HC Wainwright analyst A. Fein forecasts that the company will post earnings per share of $7.05 for the year. HC Wainwright has a “Buy” rating and a $200.00 price target on the stock. The consensus estimate for Palvella Therapeutics’ current full-year earnings is ($3.69) per share.

Other research analysts also recently issued reports about the company. Mizuho started coverage on Palvella Therapeutics in a report on Wednesday, January 7th. They issued an “outperform” rating and a $205.00 price target for the company. BTIG Research reiterated a “buy” rating and issued a $192.00 target price on shares of Palvella Therapeutics in a research note on Thursday, January 29th. Canaccord Genuity Group increased their target price on Palvella Therapeutics from $148.00 to $204.00 and gave the stock a “buy” rating in a research report on Tuesday, December 16th. UBS Group restated a “buy” rating and issued a $143.00 price target on shares of Palvella Therapeutics in a report on Monday, December 15th. Finally, Truist Financial raised their target price on shares of Palvella Therapeutics from $105.00 to $190.00 and gave the stock a “buy” rating in a research report on Monday, December 15th. Two analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $158.69.

Palvella Therapeutics Price Performance

NASDAQ:PVLA opened at $79.14 on Tuesday. The firm has a market cap of $937.02 million, a PE ratio of -30.09 and a beta of -0.16. The firm has a 50 day simple moving average of $93.89 and a 200-day simple moving average of $75.18. Palvella Therapeutics has a 1-year low of $14.68 and a 1-year high of $114.69.

Palvella Therapeutics (NASDAQ:PVLA) last released its earnings results on Monday, November 10th. The company reported ($1.03) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.18).

Insiders Place Their Bets

In related news, COO Kathleen Goin sold 4,302 shares of the firm’s stock in a transaction on Wednesday, January 21st. The stock was sold at an average price of $97.63, for a total transaction of $420,004.26. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders sold 12,906 shares of company stock valued at $1,205,980 in the last three months. Corporate insiders own 20.50% of the company’s stock.

Institutional Investors Weigh In On Palvella Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Archer Investment Corp bought a new stake in Palvella Therapeutics in the third quarter valued at approximately $28,000. Bank of America Corp DE boosted its stake in shares of Palvella Therapeutics by 12.3% in the 3rd quarter. Bank of America Corp DE now owns 4,689 shares of the company’s stock valued at $294,000 after purchasing an additional 515 shares during the last quarter. Deutsche Bank AG boosted its stake in shares of Palvella Therapeutics by 8.7% in the 4th quarter. Deutsche Bank AG now owns 6,594 shares of the company’s stock valued at $690,000 after purchasing an additional 528 shares during the last quarter. Russell Investments Group Ltd. acquired a new stake in shares of Palvella Therapeutics during the third quarter worth $36,000. Finally, JPMorgan Chase & Co. raised its stake in Palvella Therapeutics by 33.7% during the third quarter. JPMorgan Chase & Co. now owns 4,338 shares of the company’s stock worth $272,000 after buying an additional 1,093 shares during the last quarter. Institutional investors and hedge funds own 40.11% of the company’s stock.

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.